Metrics as of 10/14/2026, 10:34 PM (Berlin time), refresh in progress.
AIxCrypto Holdings, Inc.
AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing…
1D
-16.7%
1W
+32.7%
1M
+67.3%
6M
+11.1%
YTD
-35.9%
1Y
-63.9%
2Y
-82.1%
5Y
-99.8%
10Y
-100.0%
Next earnings date
17/11/2026 (in 31 days)
Volatility around earnings
~29% weaker price swings than usual
P/E
-0.15
P/B
4.89
EV/EBITDA
-1.3
RETURN ON EQUITY
-73.7%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
91.7%
FLOAT SHARES
18,558,726
AVG. DAILY VOLUME (30D)
2,051,949
AIxCrypto Holdings, Inc. is a company in the Technology sector, Software - Infrastructure industry, headquartered in United States.
The CEO is Jiawei Wang, the company employs around 10 people.
The IPO was on 23/06/2015; the stock trades on NASDAQ under the ticker AIXC.
The next earnings date is 17/11/2026.
Around past earnings, price swings were roughly -29% stronger than usual.
No, AIxCrypto Holdings currently does not pay a dividend.
Comparable stocks include Microsoft, Palantir Technologies, Oracle, Palo Alto Networks, CrowdStrike Holdings, Fortinet, Cloudflare and Synopsys.
Clicking "Analyze stock" lets five strategies assess AIxCrypto Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.